Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Jun 6;208(6):1135–1149. doi: 10.1084/jem.20101947

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 Heltemes-Harris et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 1. — Increased STAT5 activation in adult human ALL patients correlate with poor prognosis. (A) Shown are the relative levels of phospho-STAT5 (tyrosine 694/699) in cells from indicated human ALL cytogenetic subtypes (hyperdiploid, hypodiploid, immature B cell [IM], miscellaneous [Misc], no analyzable metaphases [NAM], Bcr-Abl [Ph+], pseudodiploid, diploid, t[11;14], t[4;11], t[8,14], t[8;22], and t[11;19]). Solid black bars represent the median and solid boxes represent the 25–75% range; dashed lines give ± 2 SD and open circles represent outliers. The number of samples for each subset is listed above the plot. (B) Bcr-Abl patients were separated into two equal groups representing higher (red line, n = 5) and lower (blue line, n = 6) levels of phospho-STAT5 (pSTAT5). All of these patients were subsequently treated with combination chemotherapy, including a tyrosine kinase inhibitor imatinib, and overall survival was determined. (P = 0.03, Log Rank [Mantle-Cox] test).